{"id":49633,"date":"2025-12-01T22:08:28","date_gmt":"2025-12-01T14:08:28","guid":{"rendered":"https:\/\/flcube.com\/?p=49633"},"modified":"2025-12-01T22:08:29","modified_gmt":"2025-12-01T14:08:29","slug":"humanwell-launches-rmb250m-ruicheng-venture-fund-for-health-tech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49633","title":{"rendered":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech"},"content":{"rendered":"\n<p><strong>Humanwell Healthcare (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>) announced the establishment of the <strong>Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center<\/strong> (Ruicheng Venture Capital Fund) with an <strong>initial capital of RMB\u202f250\u202fmillion<\/strong>, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing <strong>RMB\u202f75\u202fmillion<\/strong> (30%) as a limited partner.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fund-structure\">Fund Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Fund Name<\/strong><\/td><td>Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Limited Partnership)<\/td><\/tr><tr><td><strong>Lead Sponsor<\/strong><\/td><td>Humanwell Healthcare (Group) Co., Ltd. (600079.SH)<\/td><\/tr><tr><td><strong>Initial Capital<\/strong><\/td><td>RMB\u202f250\u202fmillion<\/td><\/tr><tr><td><strong>Humanwell Commitment<\/strong><\/td><td>RMB\u202f75\u202fmillion (30% of total)<\/td><\/tr><tr><td><strong>Investment Focus<\/strong><\/td><td>High\u2011tech industries within the great health sector<\/td><\/tr><tr><td><strong>Co\u2011Investors<\/strong><\/td><td>Wuhan Ruicheng Venture Capital, Hubei Chutian Fengming Science and Technology Innovation Angel Investment Fund, Wuhan Industrial Development Fund, Wuhan Changjiang New Area Innovation Industry Development Fund, Wuhan Guangchuang New Technology Venture Capital, Yin Hongtao, Tian Shui<\/td><\/tr><tr><td><strong>Fund Type<\/strong><\/td><td>Limited partnership venture capital fund<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification:<\/strong> Expands Humanwell beyond its core pharmaceutical and healthcare services into <strong>early\u2011stage health tech ventures<\/strong><\/li>\n\n\n\n<li><strong>Regional Advantage:<\/strong> Leverages Wuhan\u2019s growing biotech ecosystem and government\u2011backed innovation funds<\/li>\n\n\n\n<li><strong>Deal Flow:<\/strong> Positions Humanwell to access <strong>proprietary investment opportunities<\/strong> in drug discovery, medical devices, and digital health<\/li>\n\n\n\n<li><strong>Return Profile:<\/strong> Venture investments offer potential <strong>3\u20115x returns<\/strong> over 5\u20117 years, complementing Humanwell\u2019s operating income<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Healthcare VC Fundraising<\/strong><\/td><td>RMB\u202f85\u202fbillion (2024)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>15% (2024\u20112030)<\/td><\/tr><tr><td><strong>Wuhan Biotech Cluster Value<\/strong><\/td><td>RMB\u202f120\u202fbillion by 2027<\/td><\/tr><tr><td><strong>Target IRR for Health Tech Funds<\/strong><\/td><td>25\u201130%<\/td><\/tr><tr><td><strong>Humanwell\u2019s Strategic Value<\/strong><\/td><td>Diversified revenue stream; deal\u2011flow access for partnerships<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investment Mandate:<\/strong> Ruicheng Venture Capital Fund will focus on <strong>late\u2011preclinical to Phase\u202fII<\/strong> assets with <strong>first\u2011in\u2011class<\/strong> or <strong>best\u2011in\u2011class<\/strong> potential<\/li>\n\n\n\n<li><strong>Exit Strategy:<\/strong> Target <strong>IPO on STAR Market<\/strong> or <strong>trade sale to strategic buyers<\/strong> (including Humanwell) within <strong>5\u20117 years<\/strong><\/li>\n\n\n\n<li><strong>Next Catalyst:<\/strong> First close expected <strong>Q1\u202f2026<\/strong>; initial investments targeted <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Ruicheng Venture Capital Fund\u2019s investment strategy, return expectations, and Humanwell\u2019s strategic benefits. Actual results may differ materially due to risks including market conditions, regulatory changes, and investment performance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/600079_20251129_GXOO.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600079_20251129_GXOO.\"><\/object><a id=\"wp-block-file--media-addc9172-bfa9-4d45-bfb1-047bfc560115\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/600079_20251129_GXOO.pdf\">600079_20251129_GXOO<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/600079_20251129_GXOO.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-addc9172-bfa9-4d45-bfb1-047bfc560115\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49639,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,266,1098],"class_list":["post-49633","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-humanwell-healthcare","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Ruicheng Venture Capital Fund) with an initial capital of RMB\u202f250\u202fmillion, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing RMB\u202f75\u202fmillion (30%) as a limited partner.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49633\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech\" \/>\n<meta property=\"og:description\" content=\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Ruicheng Venture Capital Fund) with an initial capital of RMB\u202f250\u202fmillion, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing RMB\u202f75\u202fmillion (30%) as a limited partner.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49633\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T14:08:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T14:08:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech\",\"datePublished\":\"2025-12-01T14:08:28+00:00\",\"dateModified\":\"2025-12-01T14:08:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633\"},\"wordCount\":351,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101-1.webp\",\"keywords\":[\"Finance\",\"Humanwell Healthcare\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49633#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49633\",\"name\":\"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101-1.webp\",\"datePublished\":\"2025-12-01T14:08:28+00:00\",\"dateModified\":\"2025-12-01T14:08:29+00:00\",\"description\":\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Ruicheng Venture Capital Fund) with an initial capital of RMB\u202f250\u202fmillion, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing RMB\u202f75\u202fmillion (30%) as a limited partner.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49633\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49633#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech - Insight, China&#039;s Pharmaceutical Industry","description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Ruicheng Venture Capital Fund) with an initial capital of RMB\u202f250\u202fmillion, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing RMB\u202f75\u202fmillion (30%) as a limited partner.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49633","og_locale":"en_US","og_type":"article","og_title":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech","og_description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Ruicheng Venture Capital Fund) with an initial capital of RMB\u202f250\u202fmillion, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing RMB\u202f75\u202fmillion (30%) as a limited partner.","og_url":"https:\/\/flcube.com\/?p=49633","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-01T14:08:28+00:00","article_modified_time":"2025-12-01T14:08:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49633#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49633"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech","datePublished":"2025-12-01T14:08:28+00:00","dateModified":"2025-12-01T14:08:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49633"},"wordCount":351,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49633#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp","keywords":["Finance","Humanwell Healthcare","SHA: 600079"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49633#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49633","url":"https:\/\/flcube.com\/?p=49633","name":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49633#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49633#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp","datePublished":"2025-12-01T14:08:28+00:00","dateModified":"2025-12-01T14:08:29+00:00","description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New Drug Achievement Transformation Venture Capital Fund Center (Ruicheng Venture Capital Fund) with an initial capital of RMB\u202f250\u202fmillion, targeting high\u2011tech investments in the healthcare sector, with Humanwell committing RMB\u202f75\u202fmillion (30%) as a limited partner.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49633#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49633"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49633#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp","width":1080,"height":608,"caption":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49633#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0101-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49633"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49633\/revisions"}],"predecessor-version":[{"id":49640,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49633\/revisions\/49640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49639"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}